The Government is committed to ensuring that the UK Rare Disease Framework is a success and will continue to engage with a range of stakeholders before publishing action plans that outline how the priorities and underlying themes in the Framework will be addressed.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-03-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-22T11:29:06.927Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Skin Cancer: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will engage with the rare disease and blood cancer communities to ensure that rare conditions such as mycosis fungoides and Sézary syndrome, two subtypes of skin lymphoma, are considered when drafting the UK Rare Disease Framework national action plans.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158004"} , {"_about" : "http://data.parliament.uk/resources/1289682", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1289682/answer", "answerText" : {"_value" : "
No such assessment has been made.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"} } , "answeringMemberConstituency" : {"_value" : "Charnwood"} , "answeringMemberPrinted" : {"_value" : "Edward Argar"} , "dateOfAnswer" : {"_value" : "2021-03-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-16T16:36:42.1Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cutaneous T-cell Lymphoma: Diagnosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of a national campaign on differential diagnosis between common skin conditions such as eczema and psoriasis and Cutaneous T-Cell Lymphoma, a very rare type of blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158005"} , {"_about" : "http://data.parliament.uk/resources/1289683", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1289683/answer", "answerText" : {"_value" : "
We will continue to engage with a range of stakeholders, including the rare blood cancer community, before publishing action plans that outline how the priorities and underlying themes in the Framework will be addressed.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-03-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-17T15:18:14.28Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cutaneous T-cell Lymphoma: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the UK Rare Disease Framework, what steps he plans to take to engage with the rare blood cancer community to improve care coordination for people living with mycosis fungoides and Sézary syndrome, two subtypes of Cutaneous T-Cell Lymphoma, a rare blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158006"} , {"_about" : "http://data.parliament.uk/resources/1289685", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1289685/answer", "answerText" : {"_value" : "
Cancer Alliances have pathways in place to support diagnosis of T-cell lymphomas as part of their skin cancer pathways. No recent assessment on Sézary syndrome or Mycosis Fungoides has been made. However, the National Institute for Health and Care Excellence is due to publish guidance on the use of mogamulizumab for previously treated mycosis fungoides and Sézary syndrome at the end of March 2021.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-03-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "158008"} , {"_value" : "158009"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-22T11:28:43.33Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cutaneous T-cell Lymphoma: Diagnosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) improve early diagnosis of mycosis fungoides and Sézary syndrome, two subtypes of Cutaneous T-cell lymphoma and (b) ensure adults with that condition are not misdiagnosed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158007"} , {"_about" : "http://data.parliament.uk/resources/1289686", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1289686/answer", "answerText" : {"_value" : "
Cancer Alliances have pathways in place to support diagnosis of T-cell lymphomas as part of their skin cancer pathways. No recent assessment on Sézary syndrome or Mycosis Fungoides has been made. However, the National Institute for Health and Care Excellence is due to publish guidance on the use of mogamulizumab for previously treated mycosis fungoides and Sézary syndrome at the end of March 2021.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-03-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "158007"} , {"_value" : "158009"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-22T11:28:43.377Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cutaneous T-cell Lymphoma: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the adequacy of treatment provisions for people diagnosed with advanced-stage of mycosis fungoides and Sézary syndrome, two subtypes of Cutaneous T-Cell Lymphoma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158008"} , {"_about" : "http://data.parliament.uk/resources/1289687", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1289687/answer", "answerText" : {"_value" : "
Cancer Alliances have pathways in place to support diagnosis of T-cell lymphomas as part of their skin cancer pathways. No recent assessment on Sézary syndrome or Mycosis Fungoides has been made. However, the National Institute for Health and Care Excellence is due to publish guidance on the use of mogamulizumab for previously treated mycosis fungoides and Sézary syndrome at the end of March 2021.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-03-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "158007"} , {"_value" : "158008"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-22T11:28:43.423Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cutaneous T-cell Lymphoma: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Government has taken to enable equitable access to treatment and care for people living with mycosis fungoides and Sézary syndrome, two subtypes of Cutaneous T-cell lymphoma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158009"} , {"_about" : "http://data.parliament.uk/resources/1287944", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1287944/answer", "answerText" : {"_value" : "
Company directors who are also owner managers can earn a salary and receive shareholder dividends from their company as part of their total remuneration package. Company directors who pay themselves a salary through PAYE are eligible for the Coronavirus Job Retention Scheme (CJRS), but neither the CJRS nor the Self-Employment Income Support Scheme (SEISS) cover dividends or other investment income.<\/p>
<\/p>
The SEISS relies on the information provided through tax returns to determine eligibility for the scheme and to calculate the grant amount. These returns are also used to protect the scheme from abuse by organised crime groups and fraudulent operators; when an individual applies to the SEISS, HMRC can cross-check the person\u2019s SEISS application against their tax returns.<\/p>
<\/p>
It is not possible under current reporting mechanisms for HMRC to distinguish between dividends paid in lieu of employment income and those paid as returns on investment in the company. The Government has considered proposals under which company directors would be allowed to self-certify how much of their dividends are in lieu of salary, and then claim SEISS based on that self-certification. However, it is clear that this would open up the scheme to an unacceptable risk of opportunistic fraud and criminal activity.<\/p>
<\/p>
Those not eligible for the CJRS and SEISS may still be eligible for other elements of the support available. The Universal Credit standard allowance has been temporarily increased for 2020-21 and the Minimum Income Floor relaxed for the duration of the crisis, so that where self-employed claimants' earnings have fallen significantly, their Universal Credit award will have increased to reflect their lower earnings. In addition to this, they may also have access to other elements of the package, including Bounce Back loans, tax deferrals, rental support, mortgage holidays, self-isolation support payments and other business support grants.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3991", "label" : {"_value" : "Biography information for Jesse Norman"} } , "answeringMemberConstituency" : {"_value" : "Hereford and South Herefordshire"} , "answeringMemberPrinted" : {"_value" : "Jesse Norman"} , "dateOfAnswer" : {"_value" : "2021-03-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-02T13:18:18.35Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "Treasury"} , "date" : {"_value" : "2021-02-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Directors: Coronavirus"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Chancellor of the Exchequer, if he will review self-certification tax declaration rules which currently prevent small company directors being able to access covid-19 support packages.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "156335"} , {"_about" : "http://data.parliament.uk/resources/1288060", "AnsweringBody" : [{"_value" : "Ministry of Justice"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1288060/answer", "answerText" : {"_value" : "
A cross-government working group has been convened to consider the issues raised in relation to access to matured Child Trust Funds for those who lack mental capacity. The group has representation from Her Majesty\u2019s Treasury, Her Majesty\u2019s Revenue and Customs, the Department for Work and Pensions and the Ministry of Justice. Learning Disability England and MENCAP are also engaged and providing valuable input to this work. We recognise that there are many individuals and advocacy groups who have an interest in this work, and we will ensure that we continue to engage with interested groups as proposals develop.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4481", "label" : {"_value" : "Biography information for Alex Chalk"} } , "answeringMemberConstituency" : {"_value" : "Cheltenham"} , "answeringMemberPrinted" : {"_value" : "Alex Chalk"} , "dateOfAnswer" : {"_value" : "2021-03-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-02T14:34:09.877Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "54"} , "answeringDeptShortName" : {"_value" : "Justice"} , "answeringDeptSortName" : {"_value" : "Justice"} , "date" : {"_value" : "2021-02-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Child Trust Fund: Learning Disability"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Justice, pursuant to the Answer of 22 February 2021 to Question 153196, whether he has made an assessment of the potential merits of including parent and voluntary sector representation on the cross-government working group that has been established to look at the issues raised in relation to accessing matured Child Trust Funds (CTFs) in light of the Mental Capacity Act.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "156336"} , {"_about" : "http://data.parliament.uk/resources/1286392", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1286392/answer", "answerText" : {"_value" : "
All 18 year olds can access the funds from a Child Trust Fund as they would any other account, whether or not they have learning disabilities.<\/p>
Where the young adult does not have the mental capacity to provide instructions to the account manager, the Mental Capacity Act 2005 and its equivalents in Scotland and Northern Ireland makes provision for another person to provide instructions on their behalf.<\/p>
A cross-government working group comprising representatives from MOJ, HMT, HMRC and DWP has been established to look at the issues raised in relation to accessing matured Child Trust Funds (CTFs) in the light of the Mental Capacity Act.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4051", "label" : {"_value" : "Biography information for John Glen"} } , "answeringMemberConstituency" : {"_value" : "Salisbury"} , "answeringMemberPrinted" : {"_value" : "John Glen"} , "dateOfAnswer" : {"_value" : "2021-02-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-02-22T10:00:08.837Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "Treasury"} , "date" : {"_value" : "2021-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Child Trust Fund: Learning Disability"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Chancellor of the Exchequer, if he will review ease of access arrangements to Child Trust Fund accounts for 18 year olds with learning disabilities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "153196"} , {"_about" : "http://data.parliament.uk/resources/1285628", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1285628/answer", "answerText" : {"_value" : "
Public Health England will monitor vaccine effectiveness in different targeted groups using a range of existing surveillance systems, new enhanced surveillance and by building upon established research studies in specific populations.<\/p>
UK Research and Innovation has provided initial funding of £1.8 million towards the OCTAVE study in supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia and bone marrow transplants.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-03-26", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-26T14:13:47.57Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-02-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of covid-19 vaccinations for (a) people with blood cancer and (b) other immunocompromised people.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "152471"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-answer.questionFirstAnswered.=2020-11-18T13%3A04%3A24.787Z&tablingMemberConstituency=Crawley&max-date=2021-02-24", "page" : 0, "startIndex" : 1, "totalResults" : 42, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }